

1 **Test-retest reliability and criterion validity of the Spanish Version of two Motor**
2 **Imagery questionnaires in people with Parkinson Disease**

3

4

5 **Abstract**

6 **Background and purpose.** The Kinesthetic and Visual Imagery Questionnaire (KVIQ)
7 and Movement Imagery Questionnaire-Revised Second version (MIQ-RS) are
8 measurement instruments that assess motor imagery vividness. The aim was to examine
9 the validity and reliability of the Spanish KVIQ and MIQ-RS in people with Parkinson
10 Disease (PD).

11 **Methods.** A longitudinal descriptive study was conducted following the COSMIN
12 standards. Thirty-five people with idiopathic PD were assessed twice (7-15 days apart)
13 with the Spanish KVIQ and MIQ-RS. Structural validity, internal consistency, test-
14 retest reliability (ICC), standard error of measurement (SEM), smallest detectable
15 change (SDC) and criterion validity of the MIQ-RS and KVIQ long (KVIQ-20), short
16 (KVIQ-10) and extended (KVIQ-34) versions and their subscales (if pertinent) were
17 tested.

18 **Results.** Factor Analysis was satisfactory for the MIQ-RS, KVIQ-20 and KVIQ-10
19 questionnaires, providing evidence of their two-dimensional structure. Evidence of the
20 structural validity of the KVIQ-34 was not confirmed and thus was analysed as an
21 overall score. Revelle's Omega >0.9 showed excellent internal consistency. Test-retest
22 reliability was moderate (ICC = 0.58-0.75) and higher for all visual subscales. SEM and

23 SDC were up to 14.39% and 39.89% of the scores, respectively. Criterion validity
24 between questionnaires and subscales was strong (Spearman's $r > 0.7$).

25 **Discussion and conclusions.** The results provide evidence of the validity and reliability
26 of the Spanish MIQ-RS, KVIQ-20 and KVIQ-10 to assess motor imagery vividness in
27 people with PD, whereas the KVIQ-34 should only be interpreted as an overall score.
28 Psychometric, procedural and practical features of the questionnaires should be
29 considered when applying them into clinical practice.

30 **Key words:** Motor Imagery; Vividness; Assessment; Parkinson Disease; Test-retest
31 reliability

32 The Video Abstract of this article can be consulted at [this URL](#).

33 **Introduction**

34 Mental practice with Motor Imagery (MI) has been widely and successfully used to
35 improve motor performance in both sports^{1,2} and musical disciplines³ through the
36 promotion of motor learning.⁴ However, evidence of its effectiveness on
37 neurodegenerative diseases such as Parkinson Disease (PD) is conflicting. Several
38 studies have shown promising results, with body schema,⁵ mobility, motor function⁶ or
39 gait speed⁷ improvements, whereas others have found no significant differences in
40 comparison to relaxation⁸ or conventional physiotherapy⁹ interventions. The ability of
41 the person to perform MI has been identified as one of the possible factors that may
42 influence the effectiveness of MI-based programmes.¹⁰ Hence, assessing MI ability is
43 relevant in order to efficiently implement these procedures in specifically suitable
44 clinical groups which might benefit from them to a greater extent.

45 MI ability can be assessed with biological or behavioural procedures. Behavioural
46 assessments evaluate specific domains of motor images such as temporal accuracy (i.e.,
47 the time congruence between actual and imaged actions), controllability (i.e., the ability
48 to mentally manipulate images) or vividness (i.e., the subjective intensity with which a
49 person experiences MI). These aspects are assessed with separate tests such as mental
50 chronometry, mental rotation or questionnaires, respectively.^{11,12} Specifically, vividness
51 questionnaires are widespread tools typically distinguishing between the two main
52 sensory modalities used during imagery (i.e., visual and kinesthetic).¹³ There are plenty
53 of questionnaires currently available,¹⁴ but two of the most widely used in clinical
54 contexts are the Kinesthetic and Visual Imagery Questionnaire (KVIQ) and the
55 Movement Imagery Questionnaire-Revised Second Version (MIQ-RS), both
56 specifically developed for people with sensory-motor disabilities.^{15,16} Evidence of the
57 validity of the English KVIQ in people with PD is available,¹⁷ whereas there is a lack of

58 studies providing evidence of the validity and reliability of the MIQ-RS. These tools
59 represent an inexpensive, fast and useful procedure to detect poor or good imagers and
60 therefore may optimise MI-based treatments by identifying who is more suitable to be
61 trained with mental practice techniques and selecting therapeutic strategies based on
62 performance.

63 Multiple trans-cultural adaptations and translations into several languages are now
64 available for both questionnaires,¹⁸⁻²¹ as well as evidence of good psychometric
65 properties in people with stroke or Multiple Sclerosis.^{15,22,23} Although the KVIQ has
66 been used in people with PD,²⁴⁻²⁷ the usage of the MIQ-RS is much more limited due to
67 a paucity of psychometric studies. Previous work consistently shows that both
68 questionnaires have a two-dimensional structure, therefore assessing visual or
69 kinesthetic vividness separately.^{15,16,23} There is also evidence of excellent internal
70 consistency (Cronbach's alpha = 0.87-0.98), acceptable to moderate test-retest
71 reliability (ICC: KVIQ = 0.81-0.9; MIQ-RS = 0.54-0.73) and good criterion validity
72 between them.^{15,23} Nonetheless, their psychometric behaviour remains largely
73 unexamined in people with PD. No studies to date have analysed the validity of the
74 MIQ-RS in these people, though Randhawa, Harris & Boyd (2007) assessed test-retest
75 reliability of the English KVIQ and its criterion validity with the MIQ-R (first revised
76 version) in a small sample of mild to moderate PD participants (n = 11).¹⁷ However,
77 they did not evaluate its factor structure or internal consistency which should be
78 previously examined according to current consensus-based standards.²⁸ In addition, the
79 MIQ-R includes difficult movements (e.g., jumping) and thus is not the most
80 appropriate questionnaire in people with sensory-motor deficits, who should be assessed
81 with the MIQ-RS.²⁹

82 Spanish translations of the MIQ-RS and KVIQ questionnaires are recently available,
83 which allows to examine their appropriateness to evaluate MI ability in Spanish-
84 speaking clinical populations.^{30,31} Therefore, the purpose of this study was to assess the
85 psychometric properties of these two Spanish versions of the questionnaires in people
86 with PD. We aimed to (1) assess structural validity to evaluate their two-dimensional
87 structure (2) examine internal consistency and test-retest reliability of total and subscale
88 scores individually, if pertinent (3) evaluate criterion validity by correlating their total
89 and subscale scores.

90 **Methods**

91 *Study design*

92 This study followed the COnsensus-based Standards for the selection of health
93 Measurement INstruments (COSMIN) guidelines.²⁸ A descriptive longitudinal study at
94 the Madrid Parkinson Association was carried out. The study was approved by the
95 Ethical Committee for Clinical Research of the San Carlos Hospital of Madrid and
96 written informed consent from all participants was obtained prior to enrolment. All
97 procedures were in accordance with the 1964 Declaration of Helsinki.

98 *Participants*

99 *Sample size calculation*

100 Sample size was calculated using previous models proposed for test-retest reliability
101 studies using an asymmetrical interval procedure for not achieving a prespecified lower
102 limit.³² The prespecified value (p_0) was $ICC \leq 0.5$ for unacceptable reliability,³³ with a
103 95% probability of not obtaining that value. The expected value of ICC was ≥ 0.8 based
104 on previous literature.¹⁷ Thirty-two participants were needed to reach a significance

105 level of 0.05 and test power of 0.8, but considering a dropout rate of 10%, 35
106 participants were required. This calculation was performed in Microsoft Excel 2016.

107 *Selection criteria*

108 Participants were included when they were (1) diagnosed of idiopathic PD (according to
109 the United Kingdom Parkinson Disease Society Brain Bank Criteria),³⁴ (2) older than 60
110 years and (3) able to independent standing. Participants were excluded if there was
111 evidence of (1) cognitive impairment (MiniMental State Examination < 24)³⁵ or (2)
112 diagnosis of other neurological diseases than PD, psychiatric diseases, orthopaedic or
113 cardiovascular diseases, or (3) presence of visual sensory deficits (i.e., complete
114 blindness) or range of motion limitations (i.e., <80% of age-adjusted active range-of-
115 motion³⁶ in joints involved in movements assessed with the questionnaires, measured
116 with standard goniometry procedures³⁷) which could interfere with the assessments.

117 *Participants' characteristics*

118 Thirty-five people diagnosed with idiopathic PD (17 women, age = 74.2 (7.2) years),
119 with mean disease duration of 8.8 (5.9) years and in Hoehn and Yahr stages I-IV
120 participated. Impact of disease (MDS-UPDRS) and level of functional independence
121 (Schwab & England scale) are shown in Table 1. According to MDS-UPDRS data,³⁸
122 participants were subdivided into Postural Instability/Gait Difficulty (PIGD) (n=25) and
123 Tremor Dominant (TD) (n=9) motor phenotypes of PD. One participant was classified
124 as indeterminate. None of the participants had undergone Deep Brain Stimulation
125 surgery.

126 **---insert Table 1 about here---**

127 *Assessments*

128 *KVIQ Spanish Version*

129 The KVIQ questionnaire evaluates MI vividness with a difference between visual and
130 kinesthetic sensory modalities. It can be administered as short (KVIQ-10), long (KVIQ-
131 20), and extended (KVIQ-34) versions, which are additive.¹⁵ It evaluates simple
132 movements of the neck, trunk and upper and lower limbs. Limb items are administered
133 unilaterally (short and long versions), on the dominant or non-dominant side depending
134 on the item, or bilaterally (extended version). Each item involves four steps: 1) adopting
135 an initial position; 2) physically performing a movement; 3) returning to the initial
136 position, and 4) visually or kinesthetically imaging that movement. After that, the
137 participant rates the intensity perceived during the mental task on a 5-point scale, from
138 1=no image to 5=image as clear as actually seeing it (visual items) and from 1=no
139 sensation to 5=as intense as making the movement (kinesthetic items). All items are
140 first visually imaged (visual subscale) and then kinesthetically (kinesthetic subscale).
141 Performance on the questionnaire can be reported with total scores ranging from 10 to
142 50 (KVIQ-10), 20 to 100 (KVIQ-20) or 34 to 170 (KVIQ-34), subscale scores (divide
143 by two the previous ranges) and mean individual item scores (range 1 to 5), where
144 higher values mean better ability.

145 *MIQ-RS Spanish Version*

146 It is a self-administered tool that assesses imagery ease/difficulty.¹⁶ It has one version of
147 14 items with two 7-item subscales (visual and kinesthetic) whose items are
148 interspersed during the administration. Each item follows the same procedure as in the
149 KVIQ. The participant rates the easiness or difficulty of generating the image on a 7-
150 point scale from 1=very hard to see/feel to 7=very easy to see/feel, rather than the self-
151 assessed intensity of the visual or kinesthetic sensations. Scores can be recorded as total

152 (14 to 98), subscale (7 to 49) or individual item (1 to 7) values, where higher indicate
153 better ability.

154 *Experimental procedure*

155 All participants were assessed twice (7- to 15-day interval) with the paper based
156 Spanish KVIQ and MIQ-RS questionnaires by the same experienced examiner at the
157 Association facility. All participants were novel to MI techniques and were not
158 explicitly instructed to perform or not to perform mental practice between assessments.
159 Participants were not asked to change their regular medication schedule and were
160 evaluated in the “on” medication state (i.e., one to two hours after the anti-parkinsonian
161 medication intake).³⁹ Interviews confirmed that medication status did not change during
162 the period of study participation. To avoid medication-dosing effects, all participants
163 were tested at the same time of day for each of the two sessions and environmental
164 conditions remained constant during both assessments. Administration of both
165 questionnaires followed the recommendations and procedures described by their
166 original authors. In the first assessment day the KVIQ-extended version was
167 administered first and then the MIQ-RS questionnaire. In the second assessment day the
168 order was counterbalanced. We excluded participants from the analyses if any data was
169 lost after the assessments or from test to retest.

170 *Psychometric assessment and statistical analysis*

171 The Statistical Package for the Social Sciences (SPSS Statistics for Windows, Version
172 25.0. Armonk, NY: IBM Corp.) was used. All analyses were conducted with 95%
173 confidence intervals and $\alpha = 0.05$ for statistical significance. Shapiro-Wilk test for
174 data normality indicated that non-parametric statistics should be used.

175 Assessing structural validity is an essential step as a part of the psychometric analysis
176 according to COSMIN standards.²⁸ Although it is recommended that sample size should
177 be at least five times the number of items (or $n > 100$) to perform Factor Analysis, given
178 the lack of this analysis in previous studies validating MI questionnaires in people with
179 PD,¹⁷ we assessed the internal structure of each questionnaire and version (KVIQ) with
180 an Exploratory Factor Analysis. Kaiser-Meyer-Olkin and Bartlett's sphericity tests were
181 performed to determine if Factor Analysis should be used, with a cut point of >0.5 and
182 $p < 0.01$, respectively. The Principal Axis Factoring extraction method with Promax
183 rotation was used. If the bidimensional structure of the questionnaire/version was
184 confirmed, the next analyses were conducted for both total and subscale scores,
185 independently.

186 Reliability was first tested as Internal Consistency. We used Revelle's Omega total
187 coefficient, which is optimal when data are non-normally distributed and the
188 questionnaire is not unidimensional nor tau-equivalent.^{40,41} We used the RStudio
189 software (RStudio Team (2020). RStudio: Integrated Development for R. RStudio,
190 PBC, Boston, MA URL <http://www.rstudio.com/>) via calling the "omega" function
191 from the "psych" R package to obtain Omega coefficient.⁴¹ Test-retest reliability was
192 tested with the ICC using a two-way mixed-effects model with absolute agreement of
193 single measures (3,1).³³ According to COSMIN standards, there is currently no
194 consensus on whether ICCs should be replaced by non-parametric alternatives when
195 non-normal distributions are present,⁴² and thus we used this measure as the best
196 consensus-based approach.²⁸ Acceptable values were Omega > 0.7 and ICC > 0.5 .

197 Limits of Agreement were assessed with differences between first day and second day
198 tests plotted against the means of the two measurements by Bland-Altman plots.⁴³
199 Measurement error was also tested using Standard Error of Measurement (SEM) and

200 Smallest Detectable Change (SDC) with a 95% confidence interval,⁴⁴ as $SEM=SD*\sqrt{1-}$
201 ICC and $SDC= SEM*1.96*\sqrt{2}$.

202 Criterion validity between questionnaires was assessed by correlating KVIQ total and
203 subscale scores (if pertinent) to their MIQ-RS counterparts. Criterion validity of the
204 short version of the KVIQ was tested with the long version as the gold standard.⁴⁵ The
205 aforementioned analyses were tested with the Spearman's rank correlation coefficient
206 with standard interpretation⁴⁶ using the Statgraphics 19[®] software (Statgraphics
207 Technologies, Inc.).

208 **Results**

209 Thirty-five participants initially enrolled in the study completed both assessment
210 sessions, with a mean interval of 10.43 (2.56) days between test and retest, without any
211 missing data or items. Participants did not report having practised MI within the study
212 period.

213 *Motor Imagery ability*

214 Mean total, visual and kinesthetic scores of the different KVIQ versions (long, short and
215 extended), as well as MIQ-RS, are listed in Table 2. According to the Wilcoxon signed-
216 rank test there were no significant differences between visual and kinesthetic scores in
217 any of the KVIQ versions ($p = 0.929, 0.97$ and 0.606 for the KVIQ-20, KVIQ-10 and
218 KVIQ-34, respectively) or the MIQ-RS questionnaire ($p = 0.097$), suggesting equivalent
219 visual and kinesthetic vividness.

220 **---insert Table 2 about here---**

221 ***Structural validity***

222 Kaiser-Meyer-Olkin criteria for adequate measure of sampling adequacy of > 0.855,
223 with an acceptable minimum of 0.5, and Bartlett's sphericity ($X^2 \geq 479.414$, $df \geq 91$, $p <$
224 0.001) tests indicated it was pertinent to use Factor Analysis for the MIQ-RS, KVIQ-20
225 and KVIQ-10 questionnaires. However, it was not possible for the KVIQ-34 due to
226 excessively high collinearity between items, and thus its psychometric assessment was
227 performed only as a total score and not as two-dimensional tool. Two factors explained
228 the 70.63%, 67.43% and 65.08% of total variance for the MIQ-RS, KVIQ-20 and
229 KVIQ-10 questionnaires, respectively, therefore showing evidence of their two-
230 dimensional underlying structure. These factors were related between each other with r
231 = 0.6-0.63 what indicated that a non-orthogonal rotation was needed. Visual items were
232 grouped together with Factor 1, which explained 53.5-58.73% of variance, and
233 kinesthetic items did the same with Factor 2, which explained the 11.59-11.9% of
234 variance. Mean individual item scores and their factor loadings (each KVIQ version
235 independently) are shown in Table 3.

236 **---insert Table 3 about here---**

237 ***Reliability***

238 Internal consistency, test-retest reliability, SEM and SDC results are reported in Table
239 4. Wilcoxon signed-rank tests for all questionnaires and their subscales (when pertinent)
240 confirmed there were not statistically significant differences between test and retest
241 scores ($p > 0.05$), suggesting that a learning effect was absent. Revelle's Omega total
242 values ≥ 0.9 for the overall scores and subscales (when pertinent) provided evidence of
243 excellent internal consistency. ICC = 0.59-0.75 showed moderate test-retest reliability.
244 The visual subscales of all questionnaires exhibited higher ICCs than their kinesthetic

245 counterparts. Bland-Altman plots for the KVIQ-20 and MIQ-RS questionnaires are
246 shown in Figure 1.

247 **---insert Table 4 about here---**

248 **---insert Figure 1 about here---**

249 ***Criterion validity***

250 The overall and subscale scores of the KVIQ-20 were statistically significant ($p < 0.01$),
251 positively and strongly ($r > 0.7$) correlated to their MIQ-RS counterparts (Figure 2). The
252 same was found for the KVIQ-10 and the MIQ-RS correlations, thus showing evidence
253 of strong criterion validity between these measures. The KVIQ-10 was strongly and
254 significantly correlated to the KVIQ-20 for the overall, visual and kinesthetic scores
255 ($r=0.97$, $r=0.98$ and $r=0.96$, respectively; $p < 0.01$). The overall score of the KVIQ-34
256 was correlated to the MIQ-RS, KVIQ-20 and KVIQ-10 overall scores ($r=0.82$, $r=0.99$
257 and $r=0.98$; $p < 0.01$).

258 **---insert Figure 2 about here---**

259 **Discussion**

260 In this study we provide evidence of the validity (structural and criterion) and reliability
261 (internal consistency, test-retest, measurement error) of the Spanish MIQ-RS and KVIQ
262 questionnaires in people with PD. To the best of our knowledge this is the first study
263 that assesses the suitability of the MIQ-RS in this movement disorder. Our results
264 showed evidence of a good psychometric behaviour of the MIQ-RS and the long and
265 short versions of the KVIQ, in comparison to its extended version whose factor
266 structure could not be confirmed.

267 Our observations are in accordance with previous studies showing evidence of the two-
268 dimensional structure of these instruments in people with stroke and Multiple
269 Sclerosis.^{15,22} Here, we further found that the Spanish short and long KVIQ versions as
270 well as the MIQ-RS showed equivalent structural validity and excellent internal
271 consistency in people with PD. However, in our study, it was only possible to extract
272 the two theoretical factors in the long and short KVIQ versions, since very high
273 collinearity between items was found in the extended version. This reflected that some
274 dominant or non-dominant upper and lower limb items were nearly totally predicted by
275 the others, contained in the KVIQ-20, and therefore in this version the score should not
276 be interpreted as two separate subscales but as an overall score.⁴⁷ The problem of high
277 collinearity is a well-known limitation of long psychometric questionnaires measuring
278 closely related constructs,⁴⁸ where some redundancy is expected between items.⁴⁹ This
279 was illustrated by Revelle's Omega total ≥ 0.95 for the total and visual KVIQ-20/MIQ-
280 RS and total KVIQ-34 scores in our study. In this context, perhaps the use of the KVIQ-
281 10 is recommendable as there is evidence of its appropriate factor structure and
282 excellent internal consistency as well as good test-retest reliability and similar
283 measurement error.

284 Test-retest reliability assessment yielded lower ICCs than previous studies which
285 analysed the English KVIQ-34 or the German KVIQ-20/-10 in people with PD.^{17,18} The
286 English version accomplished almost excellent reliability for the total, visual and
287 kinesthetic scores (ICC > 0.8), whereas the German version showed lower data for the
288 KVIQ-20 (ICC = 0.86, 0.68 and 0.82, respectively) or the KVIQ-10 subscales (ICC =
289 0.69 (visual) and 0.84 (kinesthetic)). However, our results showed ICCs ranging from
290 0.58 to 0.69 which substantially differ from these previous studies. While the non-
291 normal distribution of our data might have influenced the values of the ICC,⁴² other

292 factors might explain these inconsistencies as well. For instance, previous work used a
293 one-way random-effects model of the ICC but a two-way mixed-effects one should be
294 used when assessing test-retest reliability.³³ Additionally, the type and definition of the
295 ICC was not specified, which is relevant in the process of selecting and reporting.
296 Moreover, sample sizes were significantly smaller (n=11 and n=8 vs n=35) and
297 participants had different clinical characteristics (e.g., Hoehn and Yahr stage 1-2.5¹⁷ or
298 mean disease duration of 5.2 (3.4) years¹⁸ vs stages 1-4 or disease duration of 8.8 (5.9)
299 years in our study). These elements should be considered when interpreting ICCs of the
300 different translations and versions of the KVIQ in people with PD, which may have
301 been overestimated in previous literature. Conversely, the MIQ-RS showed test-retest
302 reliability similar to previous studies,²³ ICCs ranging from 0.67 to 0.75 which is likely
303 to reflect the consistency of MI questionnaires over time more appropriately.

304 Consistent positive strong correlations between questionnaires suggested high criterion
305 validity, which is in accordance with precedent works.^{17,23} Nonetheless, both
306 instruments should not be used interchangeably in clinical practice, as there are
307 substantial differences between them. On the one hand, the KVIQ evaluates simpler and
308 joint-specific movements of the neck, trunk and upper/lower limbs (e.g., neck flexion,
309 hand finger-tapping, hip abduction or foot stepping), though their functional
310 significance is reduced. However, the MIQ-RS assesses functionally meaningful
311 movements but with an almost exclusive focus on upper limb tasks (e.g., grasping a
312 glass and lifting it off a table or opening a door). On the other hand, in our experience
313 the administration of the KVIQ long and extended versions takes up to thirty minutes
314 but the MIQ-RS and the KVIQ short version need over ten minutes, which is of
315 importance when evaluating their applicability to clinical practice. These differences

316 should be considered when administering them to people with PD, as well as the
317 psychometric properties obtained in this study.

318 The results obtained in this work should be interpreted considering the clinical
319 characteristics of the participants enrolled. For instance, PIGD motor phenotype of PD
320 was present in most participants (n=25), and this fact might have impacted on the
321 psychometric analyses considering there is evidence suggesting that tremor may modify
322 MI by modulating central somatosensory processing.⁵⁰ Nevertheless, the effect of PD
323 motor phenotype (PIGD or TD) on imagery ability remains largely unexplored.

324 Additionally, despite participants were in a broad range of Hoehn and Yahr stages (1-4),
325 mild to moderate stages (1.5-3) were predominant (n=31). Specifically, most
326 participants were in stages 2.5 or 3 (n=21), which is of importance considering that MI
327 ability seems to correlate with disease severity (measured with the MDS-UPDRS) in
328 “on” medication states.⁵¹ However, there is parallel evidence showing non-significant
329 correlations between measures of imagery ability and Hoehn and Yahr scale.^{24,52} Future
330 lines of work with larger sample sizes may be opened in light of these inconsistencies.

331 *Study limitations*

332 Due to the specific clinical characteristics of the participants regarding their motor
333 phenotype or Hoehn and Yahr stage, the generalisability of our results is limited. Some
334 methodological limitations should also be considered. First, we intentionally used a
335 counterbalanced order in the second assessment day to avoid learning effects, but this
336 fact could have affected test-retest reliability producing an order effect. In addition, we
337 used ICCs to assess test-retest reliability despite our data showed non-normal
338 distributions across all variables studied. Because ICC assumes data to be normally

339 distributed, this may have affected the results.⁵³ Nonetheless, there is currently no
340 international consensus on alternatives to the ICC in such cases.⁴²

341 Second, questionnaires were administered in the “on” medication state, which limits the
342 applicability of our results, despite motor fluctuations appear to not significantly modify
343 MI ability.⁵¹ Finally, even though our sample size was sufficient to evaluate test-retest
344 reliability,³² it should be considered small by the requirements of the COSMIN
345 guidelines for assessing structural validity using Factor Analysis.²⁸ However,
346 Exploratory Factor Analysis can be used in studies with $n < 50$ under some conditions
347 that apply to this work, such as high factor loadings, low number of factors or high
348 number of variables.⁵⁴

349 *Clinical implications*

350 Our results have several contributions to clinical practice. MI ability assessment in
351 Spanish-speaking people with PD can now be conducted accurately using two easily
352 administered, simply interpretable and inexpensive measures. This is a major advantage
353 for clinicians as other assessment methods of imagery ability (i.e., neuroimage
354 techniques or electrophysiological measures) require complex procedures, expensive
355 equipment and extensive experience by the examiner, which limits their clinical
356 usability, applicability and interpretability. Furthermore, SEMs and SDCs of the
357 questionnaires are provided. Therefore, clinical practitioners aiming to use Mental
358 Representation techniques (MI or Action Observation) can evaluate MI ability with
359 these tools and determine precisely how this capacity changes with training
360 programmes.

361 MI modality-specific vividness can be independently assessed with these measures, that
362 are able to distinguish between Visual and Kinesthetic imagery. Importantly, it is not

363 mandatory to complete the whole questionnaires, as subscales can be administered in
364 isolation, which may be of interest in specific clinical contexts. Last, there is evidence
365 of the validity and reliability of the KVIQ short version (KVIQ-10), which can be now
366 administered to people with PD and it is significantly less time-consuming than its long
367 counterpart.

368 **Conclusions**

369 The results provide evidence of the validity and reliability of the Spanish MIQ-RS and
370 KVIQ long and short versions to assess MI vividness in people with PD. The KVIQ
371 extended version (KVIQ-34) should be used cautiously because there is no evidence of
372 an adequate structural validity in this population.

373 **Acknowledgements**

374 We want to thank all the participants for their time and willingness. We want to thank
375 Dr. Carmen Bravo-Llatas and Rubén Fernández-Matías, PT, for their statistical advice.

376 **Supplemental Digital Content**

377 Supplemental Digital Content 1. Video Abstract.

378 **References**

- 379 1. Dana A, Gozalzadeh E. Internal and External Imagery Effects on Tennis Skills
380 Among Novices. *Percept Mot Skills*. 2017;124(5):1022-1043.
381 doi:10.1177/0031512517719611
- 382 2. Slimani M, Bragazzi NL, Tod D, et al. Do cognitive training strategies improve
383 motor and positive psychological skills development in soccer players? Insights
384 from a systematic review. *J Sports Sci*. 2016;34(24):2338-2349.
385 doi:10.1080/02640414.2016.1254809
- 386 3. Keller PE. Mental imagery in music performance: Underlying mechanisms and
387 potential benefits. *Ann N Y Acad Sci*. 2012;1252(1):206-213. doi:10.1111/j.1749-
388 6632.2011.06439.x
- 389 4. Ruffino C, Papaxanthis C, Lebon F. Neural plasticity during motor learning with
390 motor imagery practice: Review and perspectives. *Neuroscience*. 2017;341:61-
391 78. doi:10.1016/j.neuroscience.2016.11.023
- 392 5. Abraham A, Hart A, Dickstein R, Hackney ME. “Will you draw me a pelvis?”
393 Dynamic neuro-cognitive imagery improves pelvic schema and graphic-metric
394 representation in people with Parkinson’s Disease: A randomized controlled trial.
395 *Complement Ther Med*. 2019;43:28-35. doi:10.1016/j.ctim.2018.11.020
- 396 6. Tamir R, Dickstein R, Huberman M. Integration of motor imagery and physical
397 practice in group treatment applied to subjects with Parkinson’s disease.
398 *Neurorehabil Neural Repair*. 2007;21(1):68-75. doi:10.1177/1545968306292608
- 399 7. El-Wishy AA, Fayez ES. Effect of locomotor imagery training added to physical
400 therapy program on gait performance in Parkinson patients: A randomized
401 controlled study. *Egypt J Neurol Psychiatry Neurosurg*. 2013;50(1):31-37.
- 402 8. Braun S, Beurskens A, Kleynen M, Schols J, Wade D. Rehabilitation with mental
403 practice has similar effects on mobility as rehabilitation with relaxation in people
404 with Parkinson’s disease: A multicentre randomised trial. *J Physiother*.
405 2011;57(1):27-34. doi:10.1016/S1836-9553(11)70004-2
- 406 9. De Melo Santiago LM, De Oliveira DA, De Macêdo Ferreira LGL, et al.
407 Immediate effects of adding mental practice to physical practice on the gait of
408 individuals with Parkinson’s disease: Randomized clinical trial.
409 *NeuroRehabilitation*. 2015;37(2):263-271. doi:10.3233/NRE-151259
- 410 10. Ruffino C, Papaxanthis C, Lebon F. The influence of imagery capacity in motor
411 performance improvement. *Exp Brain Res*. 2017;235(10):3049-3057.
412 doi:10.1007/s00221-017-5039-8
- 413 11. Collet C, Guillot A, Lebon F, MacIntyre T, Moran A. Measuring Motor Imagery
414 Using Psychometric, Behavioral, and Psychophysiological Tools. *Exerc Sport Sci*
415 *Rev*. 2011;39(2):85-92. doi:10.1097/JES.0b013e31820ac5e0
- 416 12. Williams SE, Guillot A, Di Rienzo F, Cumming J. Comparing self-report and

- 417 mental chronometry measures of motor imagery ability. *Eur J Sport Sci.*
418 2015;15(8):703-711. doi:10.1080/17461391.2015.1051133
- 419 13. Hanakawa T. Organizing motor imageries. *Neurosci Res.* 2016;104:56-63.
420 doi:10.1016/j.neures.2015.11.003
- 421 14. Melogno-Klinkas M, Núñez-Nagy S, Ubillos-Landa S. Revisión sistemática
422 sobre instrumentos de valoración de la imaginación motora para población
423 hispanohablante: Su uso en rehabilitación. *Rev Neurol.* 2017;65(9):385-395.
- 424 15. Malouin F, Richards CL, Jackson PL, Lafleur MF, Durand A, Doyon J. The
425 Kinesthetic and Visual Imagery Questionnaire (KVIQ) for Assessing Motor
426 Imagery in Persons with Physical Disabilities: A Reliability and Construct
427 Validity Study. *J Neurol Phys Ther.* 2007;31:20-29.
428 doi:10.1097/01.NPT.0000260567.24122.64
- 429 16. Gregg M, Hall C, Butler A. The MIQ-RS: A suitable Option for examining
430 movement imagery ability. *Evidence-based Complement Altern Med.*
431 2010;7(2):249-257. doi:10.1093/ecam/nem170
- 432 17. Randhawa B, Harris S, Boyd LA. The kinesthetic and visual imagery
433 questionnaire is a reliable tool for individuals with Parkinson Disease. *J Neurol*
434 *Phys Ther.* 2010;34(3):161-167. doi:10.1097/NPT.0b013e3181e1aa71
- 435 18. Schuster C, Lussi A, Wirth B, Ettlin T. Two assessments to evaluate imagery
436 ability: Translation, test-retest reliability and concurrent validity of the German
437 KVIQ and Imaprax. *BMC Med Res Methodol.* 2012;12:127-140.
438 doi:10.1186/1471-2288-12-127
- 439 19. Demanboro A, Sterr A, dos Anjos SM, Conforto AB. A Brazilian-Portuguese
440 version of the kinesthetic and visual motor imagery questionnaire. *Arq*
441 *Neuropsiquiatr.* 2018;76(1):26-31. doi:10.1590/0004-282x20170181
- 442 20. Nakano H, Kodama T, Ukai K, Kawahara S, Horikawa S, Murata S. Reliability
443 and validity of the Japanese version of the kinesthetic and visual imagery
444 questionnaire (KVIQ). *Brain Sci.* 2018;8(5). doi:10.3390/brainsci8050079
- 445 21. Loison B, Moussaddaq AS, Cormier J, et al. Translation and validation of the
446 French Movement Imagery Questionnaire - Revised Second version (MIQ-RS).
447 *Ann Phys Rehabil Med.* 2013;56(3):157-173. doi:10.1016/j.rehab.2013.01.001
- 448 22. Moghadas Tabrizi Y, Zangiabadi N, Mazhari S, Zolala F. The reliability and
449 validity study of the Kinesthetic and Visual Imagery Questionnaire in individuals
450 with Multiple Sclerosis. *Brazilian J Phys Ther.* 2013;17(6):588-592.
451 doi:10.1590/S1413-35552012005000124
- 452 23. Butler AJ, Cazeaux J, Fidler A, et al. The movement imagery questionnaire-
453 revised, second edition (MIQ-RS) is a reliable and valid tool for evaluating motor
454 imagery in stroke populations. *Evidence-based Complement Altern Med.*
455 2012;2012(497289). doi:10.1155/2012/497289
- 456 24. Heremans E, Feys P, Nieuwboer A, et al. Motor imagery ability in patients with

- 457 early- and mid-stage Parkinson disease. *Neurorehabil Neural Repair*.
458 2011;25(2):168-177. doi:10.1177/1545968310370750
- 459 25. Heremans E, D’Hooge AM, De Bondt S, Helsen W, Feys P. The relation
460 between cognitive and motor dysfunction and motor imagery ability in patients
461 with multiple sclerosis. *Mult Scler J*. 2012;18(9):1303-1309.
462 doi:10.1177/1352458512437812
- 463 26. Abraham A, Hart A, Andrade I, Hackney ME. Dynamic neuro-cognitive imagery
464 improves mental imagery ability, disease severity, and motor and cognitive
465 functions in people with Parkinson’s disease. *Neural Plast*. 2018;2018(6168507).
466 doi:10.1155/2018/6168507
- 467 27. Maillet A, Thobois S, Fraix V, et al. Neural substrates of levodopa-responsive
468 gait disorders and freezing in advanced Parkinson’s disease: A kinesthetic
469 imagery approach. *Hum Brain Mapp*. 2015;36(3):959-980.
470 doi:10.1002/HBM.22679
- 471 28. Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN study reached
472 international consensus on taxonomy, terminology, and definitions of
473 measurement properties for health-related patient-reported outcomes. *J Clin*
474 *Epidemiol*. 2010;63(7):737-745. doi:10.1016/j.jclinepi.2010.02.006
- 475 29. Williams SE, Cumming J, Ntoumanis N, Nordin-Bates SM, Ramsey R, Hall C.
476 Further validation and development of the movement imagery questionnaire. *J*
477 *Sport Exerc Psychol*. 2012;34(5):621-646. doi:10.1123/jsep.34.5.621
- 478 30. Cantalejo-Fernández M, Díaz-Arribas MJ, Fernández-de-las-Peñas C, Plaza-
479 Manzano G, Ríos-León M, Martín-Casas P. Translation and validation of the
480 Spanish Movement Imagery Questionnaire Revised Second version (MIQ-RS).
481 *PM&R*. 2021;10.1002/pm. doi:10.1002/pmrj.12546
- 482 31. Melogno-Klinkas M, Ubillos-Landa S, Nuñez-Nagy S. Kinesthetic and visual
483 motor imagery in Spanish healthy and stroke people. *PsyArxiv Prepr*.
484 2022;March 30. doi:10.31234/OSF.IO/VJ2RE
- 485 32. Zou GY. Sample size formulas for estimating intraclass correlation coefficients
486 with precision and assurance. *Stat Med*. 2012;31(29):3972-3981.
487 doi:10.1002/sim.5466
- 488 33. Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass Correlation
489 Coefficients for Reliability Research. *J Chiropr Med*. 2016;15(2):155-163.
490 doi:10.1016/j.jcm.2016.02.012
- 491 34. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of
492 idiopathic Parkinson’s disease: A clinico-pathological study of 100 cases. *J*
493 *Neurol Neurosurg Psychiatry*. 1992;55(3):181-184. doi:10.1136/jnnp.55.3.181
- 494 35. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method
495 for grading the cognitive state of patients for the clinician. *J Psychiatr Res*.
496 1975;12(3):189-198. doi:10.1016/0022-3956(75)90026-6

- 497 36. McKay MJ, Baldwin JN, Ferreira P, et al. Normative reference values for
498 strength and flexibility of 1,000 children and adults. *Neurology*. 2017;88(1):36.
499 doi:10.1212/WNL.0000000000003466
- 500 37. Norkin CC, White DJ, Torres J, et al. *Measurement of Joint Motion: A Guide to*
501 *Goniometry*. 5th ed. F.A. Davis Company; 2016.
- 502 38. Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC. How to
503 identify tremor dominant and postural instability/gait difficulty groups with the
504 movement disorder society unified Parkinson's disease rating scale: Comparison
505 with the unified Parkinson's disease rating scale. *Mov Disord*. 2013;28(5):668-
506 670. doi:10.1002/mds.25383
- 507 39. Mena MÁ, Casarejos MJ, Solano RM, García De Yébenes J. Half a century of L-
508 DOPA. *Curr Top Med Chem*. 2009;9(10):880-893.
509 doi:10.2174/156802609789378263
- 510 40. Cho E. *Making Reliability Reliable: A Systematic Approach to Reliability*
511 *Coefficients*. Vol 19.; 2016. doi:10.1177/1094428116656239
- 512 41. Mcneish D. Thanks Coefficient Alpha, We'll Take It From Here. *Psychol*
513 *Methods*. 2018;23(3):412-433. doi:10.1037/met0000144
- 514 42. Mokkink LB, Boers M, van der Vleuten CPM, et al. COSMIN Risk of Bias tool
515 to assess the quality of studies on reliability or measurement error of outcome
516 measurement instruments: a Delphi study. *BMC Med Res Methodol*.
517 2020;20(1):1-13. doi:10.1186/S12874-020-01179-5/TABLES/7
- 518 43. Gerke O. Reporting standards for a bland-altman agreement analysis: A review
519 of methodological reviews. *Diagnostics*. 2020;10(5).
520 doi:10.3390/diagnostics10050334
- 521 44. Furlan L, Sterr A. The applicability of standard error of measurement and
522 minimal detectable change to motor learning research - A behavioral study. *Front*
523 *Hum Neurosci*. 2018;12. doi:10.3389/fnhum.2018.00095
- 524 45. Prinsen CAC, Mokkink LB, Bouter LM, et al. COSMIN guideline for systematic
525 reviews of patient-reported outcome measures. *Qual Life Res*. 2018;27(5):1147-
526 1157. doi:10.1007/S11136-018-1798-3
- 527 46. Schober P, Boer C, Schwarte LA. Correlation Coefficients. *Anesth Analg*.
528 2018;126(5):1763-1768. doi:10.1213/ANE.0000000000002864
- 529 47. Schreiber JB. Issues and recommendations for exploratory factor analysis and
530 principal component analysis. *Res Soc Adm Pharm*. Published online 2020.
531 doi:10.1016/j.sapharm.2020.07.027
- 532 48. Dormann CF, Elith J, Bacher S, et al. Collinearity: a review of methods to deal
533 with it and a simulation study evaluating their performance. *Ecography (Cop)*.
534 2013;36(1):27-46. doi:10.1111/j.1600-0587.2012.07348.x
- 535 49. Streiner DL. Starting at the beginning: An introduction to coefficient alpha and

- 536 internal consistency. *J Pers Assess.* 2003;80(1):99-103.
- 537 50. Helmich RC, Bloem BR, Toni I. Motor imagery evokes increased somatosensory
538 activity in parkinson's disease patients with tremor. *Hum Brain Mapp.*
539 2012;33(8):1763-1779. doi:10.1002/hbm.21318
- 540 51. Peterson DS, Pickett KA, Earhart GM. Effects of levodopa on vividness of motor
541 imagery in Parkinson disease. *J Parkinsons Dis.* 2012;2(2):127-133.
542 doi:10.3233/JPD-2012-12077
- 543 52. Pickett, Kristen A. Peterson, Daniel S. Earhart GM. Motor imagery of gait tasks
544 in individuals with Parkinson disease. *J Parkinsons Dis.* 2012;2(1):19-22.
545 doi:10.3233/JPD-2012-11045
- 546 53. Mehta S, Bastero-Caballero RF, Sun Y, et al. Performance of intraclass
547 correlation coefficient (ICC) as a reliability index under various distributions in
548 scale reliability studies. *Stat Med.* 2018;37(18):2734. doi:10.1002/SIM.7679
- 549 54. F de Winter JC, Dodou D, Wieringa PA. Exploratory Factor Analysis With Small
550 Sample Sizes. *Multivariate Behav Res.* 2009;44(2):147-181.
551 doi:10.1080/00273170902794206

552

553

554

555 **Tables and Figure captions**

556 Table 1. Functional status of the participants.

Variable	Category	Mean score	SD
MDS-UPDRS	Total	59.71	18.63
	Part I	13.14	6.53
	Part II	16.17	6.85
	Part III	26.43	8.19
	Part IV	3.97	3.34
Motor Phenotype	TD	n = 9 (25.71%)	
	PIGD	n = 25 (71.43%)	
	Indeterminate	n = 1 (2.9%)	
Hoehn and Yahr Stage	1	n = 1 (2.9%)	
	1.5	n = 5 (14.3%)	
	2	n = 5 (14.3%)	
	2.5	n = 8 (22.9%)	
	3	n = 13 (37.1%)	
	4	n = 3 (8.6%)	
Schwab & England scale	40%	n = 1 (2.9%)	
	60%	n = 3 (8.6%)	
	70%	n = 4 (11.4%)	
	80%	n = 11 (31.4%)	
	90%	n = 15 (42.9%)	
	100%	n = 1 (2.9%)	

557

558 Abbreviations: MDS-UPDRS, Movement Disorders Society-Unified Parkinson's

559 Disease Rating Scale; PD, Parkinson's Disease; PIGD, Postural Instability/Gait

560 Difficulty; TD, Tremor Dominant.

561

562 Table 2. Total, visual and kinesthetic scores of the Spanish KVIQ (long, short and
 563 extended versions) and MIQ-RS questionnaires.

Questionnaire	All participants (n=35)		TD Phenotype (n=9)		PIGD Phenotype (n=25)	
	Mean	SD	Mean	SD	Mean	SD
KVIQ-20 Total	72.86	20.52	75.79	20.92	71.04	20.71
KVIQ-20 Visual	36.23	12.27	37.01	15.72	35.56	11.24
KVIQ-20 Kinesthetic	36.63	10.43	38.78	10.2	35.48	10.62
KVIQ-10 Total	37.06	10.15	38.67	9.41	36.2	10.62
KVIQ-10 Visual	18.43	6.05	18.78	7.69	18.16	5.61
KVIQ-10 Kinesthetic	18.63	5.31	19.89	4.46	18.04	5.65
KVIQ-34 Total	125.4	34.53	129.34	34.46	122.8	35.27
KVIQ-34 Visual	62.6	20.89	63.33	26.93	61.2	19.13
KVIQ-34 Kinesthetic	62.8	17.44	66.01	16.82	61.08	17.92
MIQ-RS Total	72.91	19.59	74.01	12.85	72.13	21.98
MIQ-RS Visual	37.00	11.33	36.11	13.01	37.12	11.14
MIQ-RS Kinesthetic	35.91	10.35	37.9	6.95	35.01	11.49

564

565 Note: One participant was categorized as “indeterminate” according to Motor
 566 Phenotype classification and their data is not shown in this table. Abbreviations: KVIQ-
 567 (10/20/34), Kinesthetic and Visual Imagery Questionnaire-(short/long/extended); MIQ-
 568 RS, Movement Imagery Questionnaire-Revised Second Edition; PIGD, Postural
 569 Instability/Gait Difficulty; TD, Tremor Dominant.

570 Table 3. Mean score of the individual items for the KVIQ-20, KVIQ-10 and MIQ-RS questionnaires and their factor loadings.

KVIQ-20					KVIQ-10					MIQ-RS				
Item	Mean	SD	Factor		Item	Mean	SD	Factor		Item	Mean	SD	Factor	
			1	2				1	2				1	2
Item 10Vd	3.8	1.45	0.941	-	Item 8Vd	3.74	1.42	0.91	-	Item 13 (V)	4.91	1.77	0.960	-
Item 7Vnd	3.83	1.29	0.936	-	Item 9Vnd	3.54	1.44	0.864	-	Item 10 (V)	5.23	1.76	0.902	-
Item 8Vd	3.74	1.42	0.876	-	Item 5Vd	3.91	1.31	0.741	-	Item 4 (V)	5.11	1.74	0.897	-
Item 9Vnd	3.54	1.44	0.865	-	Item 6V	3.66	1.43	0.729	-	Item 8 (V)	5.00	1.79	0.886	-
Item 2V	3.4	1.44	0.847	-	Item 3Vnd	3.57	1.5	0.722	-	Item 2 (V)	5.23	2.00	0.818	-
Item 3Vnd	3.57	1.5	0.819	-	Item 5Kd	3.69	1.28	-	0.974	Item 5 (V)	5.14	1.88	0.774	-
Item 1V	3.26	1.48	0.809	-	Item 8Kd	3.97	1.2	-	0.829	Item 14 (V)	4.89	1.90	0.753	-
Item 5Vd	3.91	1.31	0.754	-	Item 9Knd	3.71	1.2	-	0.793	Item 9 (K)	5.34	1.76	-	0.897
Item 4Vd	3.51	1.54	0.734	-	Item 6K	3.63	1.29	-	0.714	Item 6 (K)	5.46	1.68	-	0.864
Item 6V	3.66	1.43	0.694	-	Item 3Knd	3.63	1.46	-	0.505	Item 7 (K)	5.43	1.78	-	0.858
Item 10Kd	3.86	1.22	-	0.985	Mean	3.71	1.35	-	-	Item 11 (K)	5.11	1.85	-	0.828
Item 5Kd	3.69	1.28	-	0.922						Item 12 (K)	5.29	1.65	-	0.811
Item 8Kd	3.97	1.2	-	0.88						Item 3 (K)	5.37	1.80	-	0.587
Item 9Knd	3.71	1.2	-	0.808						Item 1 (K)	5.40	1.80	-	0.569
Item 7Knd	3.86	1.22	-	0.772						Mean	5.20	1.80	-	-
Item 6K	3.63	1.29	-	0.76										
Item 4Kd	3.51	1.31	-	0.75										
Item 1K	3.37	1.33	-	0.664										

Item 2K	3.4	1.46	-	0.555
Item 3Knd	3.63	1.46	-	0.537
Mean	3.64	1.36	-	-

571 Factor loadings < 0.2 have been removed. Abbreviations: V, Visual; K, Kinesthetic; d, Dominant side; nd, non-Dominant side.

572 Table 4. Reliability results of the total, visual and kinesthetic scores for the KVIQ
 573 (short, long and extended versions) and MIQ-RS questionnaires.

	Revelle's Omega total coefficient	Day 1		Day 2		ICC (95% CI)	SEM	SDC
		Mean	SD	Mean	SD			
KVIQ-20 Total	0.97	72.86	20.52	78.94	16.33	0.663 (0.410-0.818)	11.92	33.02
KVIQ-20 Visual subscale	0.96	36.23	12.27	40.02	9.33	0.656 (0.395-0.815)	7.19	19.94
KVIQ-20 Kinesthetic subscale	0.94	36.63	10.43	38.91	8.73	0.585 (0.323-0.765)	6.72	18.63
KVIQ-10 Total	0.94	37.06	10.15	39.94	8.17	0.673 (0.428-0.823)	5.56	15.41
KVIQ-10 Visual subscale	0.91	18.43	6.05	20.17	4.64	0.674 (0.425-0.824)	3.3	9.14
KVIQ-10 Kinesthetic subscale	0.9	18.63	5.31	19.77	4.49	0.604 (0.349-0.777)	3.3	9.14
KVIQ-34 Total	0.97	125.4	34.53	134.06	27.31	0.692 (0.463-0.833)	19.16	53.12
MIQ-RS Total	0.97	72.91	19.59	71.77	17.63	0.681 (0.452-0.825)	11.15	30.9
MIQ-RS Visual Subscale	0.96	37.00	11.33	36.40	10.34	0.752 (0.562-0.867)	5.71	15.83
MIQ-RS Kinesthetic Subscale	0.92	35.91	10.34	35.37	9.37	0.671 (0.437-0.819)	5.99	16.59

574

575 Abbreviations: ICC, Intraclass Correlation Coefficient; SDC, Smallest Detectable

576 Change; SEM, Standard Error of Measurement.

577 **Figure 1. Bland-Altman plots for the total, visual and kinesthetic scores of the**
578 **Spanish KVIQ-20 and MIQ-RS questionnaires.** Panels A-C show plots for the MIQ-
579 RS and D-F for the KVIQ-20. Each panel show the difference between test and retest
580 plotted against the mean of the two days. The mean difference (continuous line) and
581 upper and lower limits for a 95% confidence interval (discontinuous lines) are shown in
582 blue, red and green for the total, visual and kinesthetic scores of both questionnaires,
583 respectively.

584 **Figure 2. Spearman's rank correlation coefficients between the total and subscale**
585 **scores (if pertinent) of the Spanish KVIQ and MIQ-RS questionnaires.**